PF-04691502
- Generic Name
- PF-04691502
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27N5O4
- CAS Number
- 1013101-36-4
- Unique Ingredient Identifier
- 4W39NS61KI
- Background
PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
- Associated Conditions
- -
- Associated Therapies
- -
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01658176
Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01430585
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00927823
- Locations
- 🇺🇸
Pfizer Investigational Site, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath